{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-010445","form_type":"8-K","ticker":"PVCT","cik":"0000315545","company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","filed_at":"2022-04-19T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.179350+00:00","generated_at":"2026-06-26T06:38:46.683483+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Provectus seeks approval for 1-for-10 to 1-for-50 reverse stock split at June 22 annual meeting","bullets":["Filed preliminary proxy; meeting scheduled for June 22, 2022; record date April 25, 2022.","Reverse split ratio range is 1-for-10 to 1-for-50, applies to common stock and Series D/D-1 preferred.","Authorized share reduction proposal contingent on reverse split approval; both require stockholder approval.","Stockholders also vote on director election, executive compensation, and auditor ratification."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-010445","json":"https://secwatch.observer/filing/0001493152-22-010445.json","markdown":"https://secwatch.observer/filing/0001493152-22-010445.md","text":"https://secwatch.observer/filing/0001493152-22-010445.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/315545/000149315222010445/0001493152-22-010445-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/315545/000149315222010445/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T06:38:46.683483+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}